10-K: Nordicus Partners Corp. Annual Report Highlights

Nordicus Partners Corporation files its annual report for the fiscal year ended March 31, 2026, detailing its preclinical biotech developments, acquisitions, and financial performance.

Summary

• Nordicus Partners Corporation filed its annual report for the fiscal year ended March 31, 2026.
• The company is a U.S. publicly listed biotech firm focused on developing therapeutics for unmet medical needs, particularly in oral disorders.
• Key portfolio companies include Orocidin A/S (periodontitis), Bio-Convert A/S (oral leukoplakia), and NoviThera ApS (psoriasis).
• Significant events include acquisitions of Orocidin A/S and Bio-Convert A/S in 2024, and the formation of NoviThera in October 2025.
• The company experienced no revenue in fiscal year 2026, compared to $5,000 in fiscal year 2025.
• Operating expenses increased by 49% to $4,370,998 in fiscal year 2026 from $2,924,365 in fiscal year 2025.
• Net loss for fiscal year 2026 was $4,046,804, an increase from $2,917,280 in fiscal year 2025.
• The company is pursuing a Nasdaq Capital Market uplisting and is awaiting final approval.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the lack of revenue, widening net loss, and critical liquidity concerns, despite progress in preclinical development.

Positives

• Orocidin A/S has demonstrated efficacy in treating periodontitis in animal studies (Beagle Dog and Wistar Rat) with its QR-01 drug.
• Bio-Convert A/S has obtained a toxicity waiver from the Danish Medicine Agency for its QR-02 compound.
• NoviThera ApS has demonstrated biological proof of concept in a study in mice for its QR-04 compound.
• The company's portfolio diversification strategy aims to mitigate risk with significant upside potential.
• The company is actively pursuing a Nasdaq Capital Market uplisting, which could enhance visibility and access to capital.
• Significant progress in preclinical studies for Orocidin and Bio-Convert, with Phase IIa clinical trials anticipated in the first half of 2027.
• Strengthening of the Danish Krone against the U.S. Dollar resulted in a significant gain on foreign currency translation adjustments ($3,699,514 in FY2026).

Negatives

• The company reported no revenue for the fiscal year ended March 31, 2026.
• Operating expenses increased significantly by 49% to $4,370,998 in fiscal year 2026.
• Net loss widened to $4,046,804 in fiscal year 2026 from $2,917,280 in fiscal year 2025.
• The company has an accumulated deficit of $50,786,534 as of March 31, 2026.
• Cash on hand was only $20,878 as of March 31, 2026, raising substantial doubt about the ability to continue as a going concern.
• Disclosure controls and procedures, and internal control over financial reporting were deemed not effective at a reasonable assurance level due to limited resources.
• The company has not paid cash or stock dividends and has no present plan to pay any dividends.

Risks

• The company is a smaller reporting company and not required to provide detailed risk factor information.
• The company's operations are subject to risks including the results of R&D, clinical testing, regulatory approvals, competition, and the ability to raise capital.
• The company's ability to continue as a going concern is dependent on generating profitable operations and/or obtaining necessary financing.
• The company's net operating loss carryforwards may be substantially limited due to ownership change limitations under Section 382 of the Internal Revenue Code.
• The company's shares are subject to penny stock rules, which may restrict broker-dealer trading and shareholder ability to sell shares.

Future Outlook

The company aims to advance its preclinical drug candidates through Phase I development. Upon completion of Phase I, options include sale/merger, further clinical development, strategic partnerships, or an IPO. Clinical trials for Orocidin and Bio-Convert are anticipated to begin in the first half of 2027. The company is also seeking to uplist to the Nasdaq Capital Market, which could facilitate future capital raises.

Management Comments

• Management believes its portfolio diversification strategy positions it as a stable and resilient company, mitigating risk with significant upside potential.
• The company aims to take all portfolio companies' drug developments through Phase I.
• Management concluded that disclosure controls and procedures, and internal control over financial reporting were not effective at the reasonable assurance level due to limited resources in the finance and accounting functions.

Industry Context

StockSavvy.ai notes that Nordicus Partners Corporation operates in the highly competitive and capital-intensive biotechnology sector, focusing on preclinical-stage assets in niche therapeutic areas. The company's strategy of acquiring and developing drugs from Nordic biotech firms is a common approach for smaller companies seeking to leverage regional innovation.

Comparison to Industry Standards

• The company's preclinical development timeline, with Phase IIa trials anticipated in H1 2027 for Orocidin and Bio-Convert, aligns with typical industry timelines for early-stage drug development.
• The significant increase in R&D expenses (21%) reflects the industry standard for companies advancing drug candidates through preclinical and early clinical stages.
• The lack of revenue and widening net loss are characteristic of many preclinical biotechnology companies that require substantial investment before commercialization.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not the subject of any pending legal proceedings.
• To the knowledge of management, no proceedings are presently contemplated against the company by any federal, state or local governmental agency.
• To the knowledge of management, no director or executive officer is a party to any action in which such person has an interest adverse to the company.

Related Party Transactions

• Warrants issued to GK Partners ApS for financial services.
• Stock purchase and sale agreement with GK Partners ApS for equity interests in Mag Mile Capital.
• Lease agreement between NP Bioinnovation A/S and GK Partners.
• Consulting services provided by GK Partners to the Company's subsidiaries.
• Legal fees paid to an affiliate of Bennett J. Yankowitz.
• Employment and consulting agreements with CEO Henrik Rouf and CFO Bennett J. Yankowitz.
• Related party forgave a payable of $13,886 in FY2025.
• NoviThera ApS purchased intellectual property from Alteral Therapeutics (controlled by Allan Wehnert) in exchange for a 49.9% equity stake in NoviThera.

Stakeholder Impact

• Shareholders: The widening net loss and low cash balance may negatively impact share value. The potential Nasdaq uplisting could be a positive catalyst.
• Employees: Increased administrative assistance and staff salaries are noted, suggesting potential growth in headcount.
• Creditors: The company has a note payable of $60,000 to Reddington Partners LLC, classified as a current liability.

Next Steps

• Advance Orocidin A/S and Bio-Convert A/S drug developments through Phase I.
• Initiate Phase IIa clinical trials for Orocidin and Bio-Convert in the first half of 2027.
• Continue development of NoviThera ApS's psoriasis treatment.
• Await final approval for Nasdaq Capital Market uplisting.
• Secure necessary financing to meet obligations and fund operations.

Key Dates

Recommendation

The company is in the preclinical stage with promising drug candidates, but faces significant financial challenges, including a lack of revenue and critically low cash reserves, raising substantial doubt about its going concern status. While the potential Nasdaq uplisting and progress in preclinical studies are positive, the immediate financial risks necessitate a cautious 'hold' rating until further financing is secured and commercialization pathways become clearer.

Keywords

Nordicus Partners Corporation, Biotechnology, Preclinical, Periodontitis, Oral Leukoplakia, Psoriasis, SEC Filing, 10-K